Cell-Based Immunotherapy of Gliomas

Everson, Richard; Antonios, Joseph; Liau, Linda M.

doi:10.1159/000469683

Cited by 8 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TAMs are macrophages infiltrating in tumor tissues which are the main composition in tumor microenvironment (TME). They differentiate through alternative pathways, among which the most common one is Notch pathway [26, 27]. What’s more, they facilitate tumor progression [28].…”

Section: Discussionmentioning

confidence: 99%

Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma

Chen

et al. 2019

Cancer Cell Int

View full text Add to dashboard Cite

Background Tumor-infiltrating immune cells (TIICs) are highly relevant to clinical outcome of glioma. However, previous studies cannot account for the diverse functions that make up the immune response in malignant transformation (MT) from low-grade glioma (LGG) to high-grade glioma (HGG). Methods Transcriptome level, genomic profiles and its relationship with clinical practice were obtained from TCGA and CGGA database. The “Cell type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT)” algorithm was used to estimate the fraction of 22 immune cell types. We divided the TCGA and CGGA set into an experiment set (n = 174) and a validation set (n = 74) by random number table method. Univariate and multivariate analyses were performed to evaluate the 22 TIICs’ value for MT in LGG. ROC curve was plotted to calculate area under curve (AUC) and cut-off value. Results Heterogeneity between TIICs exists in both intra- and inter-groups. Several TIICs are notably associated with tumor grade, molecular subtypes and survival. T follicular helper (TFH) cells, activated NK Cells and M0 macrophages were screened out to be independent predictors for MT in LGG and formed an immune risk score (IRS) (AUC = 0.732, p < 0.001, 95% CI 0.657–0.808 cut-off value = 0.191). In addition, the IRS model was validated by validation group, Immunohistochemistry (IHC) and functional enrichment analyses. Conclusions The proposed IRS model provides promising novel signatures for predicting MT from LGG to HGG and may bring a better design of glioma immunotherapy studies in years to come.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma

Chen

et al. 2019

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Immunotherapy, including therapeutic vaccines and engineered T cells based on tumour-immune cell interactions and checkpoint blockers, has been a focus of many recent strategies for treating glioma and other cancers. [7][8][9][10][11] Therefore, we assessed the expression of immune checkpoint genes and marker genes from TILs. In…”

Section: Relationship Of Immune Response and Gliomamentioning

confidence: 99%

“…renal cancer and bladder cancer. [7][8][9][10][11] Checkpoint inhibitors, including programmed death-ligand 1 and programmed cell death protein 1 inhibitors, have emerged as potential therapeutic options for low grade glioma (LGG) and GBM. 12 Furthermore, the tumour mutational burden (TMB) has been reported as an independent prognostic factor for glioma.…”

Section: Introductionmentioning

confidence: 99%

EZH2 is a potential prognostic predictor of glioma

Chen

Hou

Jiang

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Several additional passive and active cell based immunotherapies are currently being tested and the readers are referred to comprehensive reviews of this topic. [161,162]…”

Section: Genetically Engineered T-cellsmentioning

confidence: 99%

Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target

Carpenter

Alnahhas

Gonzalez

et al. 2019

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Introduction: Gliomas are highly heterogeneous primary brain tumors which result in a disproportionately high degree of morbidity and mortality despite their locoregional occurrence. Advances in the understanding of the biological makeup of these malignancies have yielded a number of potential tumor-driving pathways which have been identified as rational targets for therapy. However, early trials of agents that target these pathways have uniformly failed to yield improvement in outcomes in patients with malignant gliomas.Areas covered: This review provides an overview of the most common biological features of gliomas and the strategies to target the same; in addition, the current status of immunotherapy and biological therapies are outlined and the future directions to tackle the challenges of therapy for gliomas are examined. Expert opinion:The limitations of current treatments are attributed to the inability of most of these agents to cross the blood brain barrier and to the intrinsic heterogeneity of the tumors that result in treatment resistance. The recent emergence of immune-mediated and biological therapies and of agents that target metabolic pathways in gliomas have provided strategies that may overcome tumor heterogeneity and ongoing trials of such agents are anticipated to yield improved outcomes.

show abstract

Cell-Based Immunotherapy of Gliomas

Cited by 8 publications

References 0 publications

Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma

Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma

EZH2 is a potential prognostic predictor of glioma

Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target

Contact Info

Product

Resources

About